logo
  

AzurRx Activates New Clinical Trial Sites In India For Gastrointestinal Infections COVID-19 Study

AzurRx BioPharma Inc. (AZRX) said that it has activated seven new clinical trial sites in India for phase 2 RESERVOIR Trial evaluating niclosamide for the treatment of COVID-19 gastrointestinal infections.

The phase 2 placebo-controlled clinical trial will confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract.

The seven new clinical trial sites in India, together with the existing eleven sites in the U.S. and the five trial sites recently added in the Ukraine, brings the total number of RESERVOIR trial sites to twenty-three. AzurRx expects to report topline results during the first quarter of 2022.

The long-term observation data could indicate that niclosamide treatment has the potential to improve "long haul" COVID-19 symptoms.

FW-1022 is a niclosamide based small molecule drug which the Company's clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections. FW-1022 is anticipated to be supplied as an oral immediate release tablet.

On Thursday, AzurRx BioPharma said that an independent data monitoring committee or DMC approved initiating patient enrollment in Part 2 of the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission or FTC, has sued Walmart for allowing its money transfer services to be used by fraudsters, who fleeced consumers out of hundreds of millions of dollars. The retail giant is alleged to have looked the other way to pocket millions in fees while scammers took advantage of its failure to properly secure the money transfer services offered at Walmart stores. Home improvement retailer Bed Bath & Beyond, Inc. (BBBY) reported on Wednesday a net loss for first quarter that sharply widened from last year, hurt by hefty transient costs related to inventory markdown reserves and port-related supply chain fees. Both adjusted loss per share and net sales missed analysts' expectations. Tesla Inc. laid off about 200 employees in its Autopilot unit as the luxury electric car maker closed down its office in San Mateo, California as part of cost cutting efforts, reports said. The San Mateo office, where employees worked on improving the driver assistance systems, marketed as Autopilot, had about 350 employees before the cut.
Follow RTT